论文部分内容阅读
目的观察降脂药物诺衡对于活动期激素耐药型肾病综合征(SR-NS)患儿高脂血症的疗效及安全性。方法观察在北京大学第一医院儿科住院的8例肝功能正常的活动期SR-NS患儿诺衡降脂治疗1个月,检测治疗前后血清脂质、脂蛋白、白蛋白、肝肾功能的变化及观察临床副反应表现,其中男6例,女2例;年龄214岁,平均8.4岁,所有患儿均接受激素治疗且用药前后尿蛋白持续+++++++。结果血脂及脂蛋白水平在用药2周后出现不同程度的变化,其中TG明显下降(P<0.05),TC、VLDL、LDL下降,HDL上升,差异均在4周后出现明显变化(P<0.05)。治疗前后血Alb、ALT、SCr差异均无统计学意义,且后两者在正常范围内。除1例服药中出现胃肠不适感外,所有患儿均无腹痛、腹泻及皮疹等副反应。结论结果显示对于持续未缓解的SR-NS患儿,尤以TG升高为主的高脂血症,短期应用诺衡降脂治疗是安全有效的,肾功能不全者慎用。
Objective To observe the efficacy and safety of the lipid-lowering drug Noble for hyperlipidemia in active steroid-resistant nephrotic syndrome (SR-NS). Methods: Eight patients with SR-NS with active normal liver function in Peking University First Hospital were enrolled in this study. One year after treatment, the serum lipid, lipoprotein, albumin, liver and kidney function were measured Changes and observation of clinical manifestations, including 6 males and 2 females; aged 214 years, mean 8.4 years, all children received hormone therapy before and after treatment urinary protein continued +++++++. Results The levels of lipids and lipoproteins changed to varying degrees after 2 weeks of treatment, in which TG decreased significantly (P <0.05), decreased TC, VLDL, LDL, increased HDL, the difference was significantly changed after 4 weeks ). Before and after treatment, the blood levels of Alb, ALT and SCr were not significantly different, and the latter two were within the normal range. In addition to 1 case of gastrointestinal discomfort in taking medication, all children without abdominal pain, diarrhea and rash and other side effects. Conclusions The results showed that short-term use of Noble lipid-lowering therapy is safe and effective for those children with persistent SR-NS, especially those with elevated TG, with caution.